Response to “Optimized Alectinib Dose Regimen for Treatment of Patients With ALK-Positive NSCLC Based on Robust Pharmacometric Analyses and Clinical Evidence”
Publication date
2021-11
Authors
Groenland, Stefanie L.
Geel, Dieuwertje R.
Beijnen, Jos H.
Smit, Egbert F.
Huitema, Alwin D.R.
Steeghs, Neeltje
Editors
Advisors
Supervisors
Document Type
Comment
Metadata
Show full item recordCollections
License
taverne
Abstract
Keywords
Carbazoles, Humans, Lung Neoplasms/drug therapy, Piperidines/adverse effects, Receptor Protein-Tyrosine Kinases, Taverne, Pharmacology (medical), Pharmacology, Comment, Letter
Citation
Groenland, S L, Geel, D R, Beijnen, J H, Smit, E F, Huitema, A D R & Steeghs, N 2021, 'Response to “Optimized Alectinib Dose Regimen for Treatment of Patients With ALK-Positive NSCLC Based on Robust Pharmacometric Analyses and Clinical Evidence”', Clinical Pharmacology and Therapeutics, vol. 110, no. 5, pp. 1164-1164. https://doi.org/10.1002/cpt.2372